“I stopped adjuvant therapy after a year. Now, 10 months later, my cancer is back. Is it too late to do something?”

Help appropriate patients who have stopped treatment establish tumour control with GLIVEC1,2*

Patient characteristics

69 years old

Gastric KIT+ GIST

Mitotic rate: ≤5/50 HPFs

23 months since diagnosis

Original tumour:
8 cm

*Tumour control is defined as complete response, partial response, or stable disease.

Patient characteristics

69 years old

Gastric KIT+ GIST

Mitotic rate: ≤5/50 HPFs

23 months since diagnosis

Original tumour:
8 cm

*Tumour control is defined as complete response, partial response, or stable disease.

Models are used for illustrative purposes only throughout the site. Patient quotes are intended for guidance only and do not reflect actual patient testimonials.

References: 1. Reichardt P, Blay J-Y, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther. 2010;10(2):221-232. 2. Blay J-Y, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25(9):1107-1113.